ATPC Expands Global Market Footprint to Spearhead Medical Innovation with MoUs in Indonesia

Through these partnerships, ATPC reaffirms its commitment to maintaining the highest standards of safety and efficacy for its health products, further solidifying its position as a trusted innovator in the healthcare industry.

The collaborations are built on a shared vision to address critical global health challenges. Together, the parties aim to foster interdisciplinary collaboration, knowledge exchange, and sustainable health practices. Key initiatives include advanced medical research, healthcare professional training, and the introduction of innovative approaches to combat respiratory diseases. The partnerships also aim to connect with international universities and specialist hospitals to further elevate healthcare standards.

Prof Dato’ Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC said, “TB and COPD remain major public health concerns in both Indonesia and Malaysia. Indonesia ranks among the countries with the highest TB burden globally, with hundreds of thousands of new cases reported annually. Meanwhile, COPD, often linked to high rates of smoking and air pollution, significantly contributes to illness and mortality in both nations. These diseases place immense strain on healthcare systems, highlighting the urgent need for collaborative efforts to improve prevention, diagnosis, and treatment strategies.”

“Our partnerships reflect ATPC’s unwavering commitment to leveraging global expertise and advancing healthcare innovation. By conducting rigorous clinical studies and aligning with Indonesia’s Ministry of Health standards, we aim to ensure that products and services like DSY Wellness, ATP2 and LEGA effectively meet the needs of patients battling respiratory diseases. This marks a pivotal step toward creating a healthier, more sustainable future. We look forward to exploring new collaborations that will further enhance our contributions to Southeast Asia’s healthcare ecosystem.”

These partnerships also emphasize the integration of sustainable medical innovations, aiming to enhance long-term well-being and align with the United Nations Sustainable Development Goals (“UNSDG”). Through these collaborations, ATPC reinforces its role as a global leader in wellness and healthcare, advancing scientific research and sustainable health outcomes.

The MoU signing ceremony was graced by distinguished guests from the Indonesian Ministry of Health, including Dr. Suranto M.Kes, Director of Health Service Governance, and Prof. Dr. Taruna Ikrar, Head of the Food and Drug Supervisory Authority (BPOM), an agency under the Ministry of Health. Also present were representatives from ATPC, including Prof. Dato' Sri Dr. How Kok Choong, Founder and Group CEO; Dr. John Vong, Deputy Chairman; and Dr. Fernando Cortizo, Executive Director.